










A



B



67	31	132	+169	205	+245	283	+25.2		38	132	+169	151	+335	283	+25.2
2	41.4	16	31	31	+14.9	35	+59.5	47		16	31	19	+256.2	35	+59.5
30	+1,929.5	26	+566.8	75	+481	95	+67.1 <sup>99</sup>			26	+566.8	68	+29.8	95	+67.1
9	+133.2	24	+89.2	44	+40.7	46	+66.3			24	+89.2	21	+46.2	46	+66.3
2		0	88.1	4		4				0	88.1	3		4	
9		25		38		47				25		22		47	

28 3												
	340	+38.7	495	692	+35.8	+0.5	1,094	+21.7	756			
36	+35.8	492	68	+19.5	5.9	107	+11.5	496				

28						
( )					(11/10 )	
692	+35.8	755	+6.6	1,447	+18.8	
68	+19.5	147	+7.4	216	+11.0	


27 3												
	245	6.4	510	31	898	+41	1,218	+7.3				
26	+3.4	57	17.6	96	11.4	194	9.7					

27					
510	31	708	+16.3	1,218	+7.3
57	17.6	137	5.9	194	9.7

28	334	287	49	2	330	252	77	0	665	540	127	2
----	-----	-----	----	---	-----	-----	----	---	-----	-----	-----	---



1,998	+0.7	1,776	105	1,656	166
3,602	+5.2	3,712	+84	3,852	+125
2,003	9.5	1,796	189	1,755	207




3,266	4.4	3,335	+27	3,733	+48	3,520	+7.0
4,560	+0.8	4,602	+0.7	4,758	+21	5,253	+16.6
4,494	3.5	4,531	+1.1	4,859	+1.1	4,970	+10.1
2,573	15.7	2,598	5.7	2,897	5.3	2,985	+14.2
1,920	+19.6	1,932	+12.1	1,962	+12.3	1,984	+4.5
3,333	+1.5	3,406	+2.0	3,632	+6.3	3,803	+15.9
3,219	+4.2	3,271	+4.8	3,411	+7.1	3,424	+7.6

1,998 .5

.5



---







28 2 5

®

SME3110

ME2112

Phase / ME2125

ME3113

Phase

®

Phase

ME1111

Phase

DMB- 3111

/

Phase

ME1100

OP0595

Ne ron Pharmaceuticals

Dong-A ST

MSD

Dong-A Socio Holdings

F.

27



28 3

28 3

28 3

26 3

27 3



A

[Redacted text]

[Redacted text]

[Redacted text]

[Redacted text]

B

[Redacted text]

[Redacted text]

[Redacted text]

[Redacted text]